Shanghai Henlius Biotech Statistics

Total Valuation

Shanghai Henlius Biotech has a market cap or net worth of HKD 12.36 billion. The enterprise value is 16.01 billion.

Market Cap	12.36B
Enterprise Value	16.01B

Important Dates

The next estimated earnings date is Friday, November 15, 2024.

Earnings Date	Nov 15, 2024
Ex-Dividend Date	n/a

Share Statistics

Shanghai Henlius Biotech has 543.49 million shares outstanding. The number of shares has increased by 0.11% in one year.

Shares Outstanding	543.49M
Shares Change (YoY)	+0.11%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.59%
Owned by Institutions (%)	6.18%
Float	68.28M

Valuation Ratios

The trailing PE ratio is 16.67 and the forward PE ratio is 18.86.

PE Ratio	16.67
Forward PE	18.86
PS Ratio	2.04
PB Ratio	4.46
P/FCF Ratio	18.29
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 12.85, with an EV/FCF ratio of 23.67.

EV / Earnings	21.52
EV / Sales	2.64
EV / EBITDA	12.85
EV / EBIT	18.71
EV / FCF	23.67

Financial Position

The company has a current ratio of 0.49, with a Debt / Equity ratio of 1.57.

Current Ratio	0.49
Quick Ratio	0.30
Debt / Equity	1.57
Debt / EBITDA	3.50
Debt / FCF	6.44
Interest Coverage	6.68

Financial Efficiency

Return on equity (ROE) is 30.99% and return on invested capital (ROIC) is 7.99%.

Return on Equity (ROE)	30.99%
Return on Assets (ROA)	5.08%
Return on Capital (ROIC)	7.99%
Revenue Per Employee	1.71M
Profits Per Employee	209,790
Employee Count	3,637
Asset Turnover	0.58
Inventory Turnover	1.90

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +125.25% in the last 52 weeks. The beta is 0.81, so Shanghai Henlius Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.81
52-Week Price Change	+125.25%
50-Day Moving Average	22.92
200-Day Moving Average	17.48
Relative Strength Index (RSI)	46.79
Average Volume (20 Days)	356,827

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Shanghai Henlius Biotech had revenue of HKD 6.06 billion and earned 743.92 million in profits. Earnings per share was 1.36.

Revenue	6.06B
Gross Profit	4.44B
Operating Income	855.46M
Pretax Income	775.10M
Net Income	743.92M
EBITDA	1.17B
EBIT	855.46M
Earnings Per Share (EPS)	1.36

Full Income Statement

Balance Sheet

The company has 715.08 million in cash and 4.36 billion in debt, giving a net cash position of -3.64 billion or -6.70 per share.

Cash & Cash Equivalents	715.08M
Total Debt	4.36B
Net Cash	-3.64B
Net Cash Per Share	-6.70
Equity (Book Value)	2.77B
Book Value Per Share	5.10
Working Capital	-2.69B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.04 billion and capital expenditures -362.61 million, giving a free cash flow of 676.13 million.

Operating Cash Flow	1.04B
Capital Expenditures	-362.61M
Free Cash Flow	676.13M
FCF Per Share	1.24

Full Cash Flow Statement

Margins

Gross margin is 73.23%, with operating and profit margins of 14.11% and 12.27%.

Gross Margin	73.23%
Operating Margin	14.11%
Pretax Margin	12.79%
Profit Margin	12.27%
EBITDA Margin	19.26%
EBIT Margin	14.11%
FCF Margin	11.16%

Dividends & Yields

Shanghai Henlius Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.11%
Shareholder Yield	-0.11%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Shanghai Henlius Biotech has an Altman Z-Score of 0.58. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.58
Piotroski F-Score	n/a